Bertilimumab  (Synonyms: CAT 213; iCo-008)

Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research^[1].

Bertilimumab (CAT 213) neutralizes the ability of eotaxin-1 to cause an increase in intracellular calcium signaling (with an IC₅₀ value of 2.86 nM), migration of CCR3-expressing L1.2 cells (with an IC₅₀ value of 0.48 nM), and inhibition of the eotaxin1-evoked shape change of human eosinophils in vitro (with an IC₅₀ of 0.71 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 μg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

375348-49-5

[Bertilimumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sarah Main, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404.  [Content Brief]